Element Biosciences filed multiple lawsuits against Illumina alleging anticompetitive conduct and patent infringement involving next-generation sequencing technologies. The complaints detail threats and exclusivity agreements by Illumina to maintain market dominance, hampering competition. The litigation escalates ongoing disputes between the two companies in the mid-throughput sequencing segment. Illumina denies the allegations and pledges vigorous defense. The case highlights growing tensions in the genomics sector over market control and innovation barriers.